Localized large cell lymphoma: Is there any need for radiation therapy?

Current Opinion in Oncology

Volumn 21, Issue 5, 2009, Pages 401-406

  Persky, Daniel O ^a   Miller, Thomas P ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE   (United States)

Author keywords

Aggressive lymphoma; Diffuse large B cell lymphoma; Early stage; Localized; Radiation therapy

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL TRIAL; FEBRILE NEUTROPENIA; HUMAN; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIOIMMUNOTHERAPY; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; TREATMENT OUTCOME;

EID: 69549135986     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832f3c8b     Document Type: Review

References (19)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780-2795.
2. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339:21-26. (Pubitemid 28304493)
3. Miller TP, LeBlanc M, Spier CM, et al. CHOP alone compared to CHOP plus radiotherapy for early state aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. Blood 2001; 98:724a.
4. Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002; 20:197-204. (Pubitemid 34032612)
5. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004; 22:3032-3038. (Pubitemid 41103714)
6. Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352:1197-1205. (Pubitemid 40397261)
7. Miller TP, Spier CM, Rimsza L. Diffuse aggressive histologies of nonHodgkin lymphoma: treatment and biology of limited disease. Semin Hematol 2006; 43:207-212. (Pubitemid 44486314)
8. Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25:787-792. (Pubitemid 350002878)
9. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242. (Pubitemid 34438862)
10. Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014. J Clin Oncol 2008; 26:2258-2263. Phase II study of rituximab added to CHOP followed by radiation therapy.
11. Miller TP, Unger JM, Spier CM, et al. Effect of adding ibritumomab tiuxetan (zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG 0313). Blood 2008; 112:11. (abstract 3598).
12. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7:379-391.
13. Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008; 9:435-444.
14. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-586. (Pubitemid 350002966)
15. Sehn L, Savage K, Hoskins P, et al. Limited-stage DLBCL patients with a negative PET scan following three cycles of R-CHOP have an excellent outcome following abbreviated immuno-chemotherapy alone. Ann Oncol 2008; 19 (Suppl 4):iv99. (abstract 052). Preliminary data from PET-directed strategy that obviate the need for consolidated radiation therapy in a large percentage of patients.
16. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21:897-906.
17. Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol 2006; 24:1568-1574. (Pubitemid 46638780)
18. Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006; 107:108-115. (Pubitemid 43939037)
19. Hemminki K, Lenner P, Sundquist J, Bermejo JL. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol 2008; 26:1850-1857.